Nanobiotix is trading at $30.14, up 5.53%, with broader biotech-sector strength providing the clearest context for the move.

  • The supplied market context shows XBI up 2.13% alongside a broad risk-on session.
  • No clear company-specific announcement has emerged on November 4.
  • The latest listed company release was October 24, reporting Phase 1 melanoma study data; sector strength supports an explanation, but does not prove a specific catalyst.